



Arjen Schippers, Senior Director and Program Head Leiden
Cell Therapy Facility

24th May 2022



01 Bristol Myers Squibb at a glance

02 What is CAR T?

03 Why Leiden Bio Science Park?

04 BMS' view on the future of cell therapy

05 Q&A

Our global presence



Sites in more than
50 countries worldwide



“

We come to work each day driven by our mission, acting with a sense of urgency for our patients and their families, because there is still so much more to do.

*- Giovanni Caforio, M.D.,
Board Chair and Chief Executive Officer*

Bristol Myers Squibb cell therapy global manufacturing network

Devens, MA



Summit, NJ



Bothell, WA



Warren, NJ



Our newest: Leiden, the Netherlands



What is CAR T?

Why CAR T is Different...

A personalized and novel cancer treatment



Not another pill



Bespoke treatments



Personalized manufacturing process



Essential medicine




Individualized supply chain



Non-traditional commercial model

Cell therapy has a wholly new delivery model

Complexity of CAR T therapy



Commitment & investment cell therapy manufacturing site Europe

- Our first cell therapy manufacturing site in Europe.
- The European site will be the company's fifth cell therapy manufacturing facility.
- There will be capabilities for multi-product manufacturing, pending regulatory approvals.



European cell therapy manufacturing site - The Netherlands

Why Leiden, The Netherlands?



Offers an attractive **international community** and top-notch **talent pool** of the industry



The **Leiden Bio Science Park is the largest life sciences cluster** in The Netherlands - **'Boston at the North Sea'**

Factors of consideration



Ability to quickly build and maintain a workforce



Easy access to intra-continental transportation



Scientific talent and capabilities

Cell Therapy Manufacturing
Site Leiden



* Ireland: Cruiserath/Dublin, Germany: Frankfurt, Munich, Leipzig, Belgium: Brussels, Spain: Madrid, Barcelona, Switzerland: Boudry.

Site development timelines



Site Scope

People

- 500+ new hires in 3 years
- Training / experience
- BMS name & brand
- 2500+ Screenings, 1500+ interviews
- Seating during CTF build

Design / Construction

- Safety is paramount
- Knowledge buildup
- Knowledge retention
- Covid impact, limited F2F
- Ukraine, material cost

Location

- Leiden is new in BMS
- No existing campus
- IT, ERP, network, GMP Lan
- Make your own culture
- LBSP is strong
- Leverage EU+

BMS' view on the future of cell therapy

Increase of capacity for treating our patients & hiring new employees



The site will have capacity for production of multiple-product cell therapies to **treat and serve more patients**, across the European markets.




It may offer **shorter turnaround times for patients** located in Europe as it **reduces shipping time** to and from treatment centers in the US.




There will be an **increase of job opportunities**, as the site will hire new employees.

The future of cell therapy




Engineered TCR T Cells for Solid Tumors

Recognizes intracellular targets




Dual Antigen Targeting CAR T

Mitigating antigen loss



CAR T Armed Payload

Overcoming tumor microenvironment resistance



Allogeneic CAR T Cells

Off-the-shelf alternative

Enabled through strategic partnering:





Questions?



Bristol Myers SquibbTM